Agranulocytosis Health Dictionary

Agranulocytosis: From 3 Different Sources


A condition in which there is a marked decrease or absence of polynuclear or granular white cells in the blood following prolonged septic conditions or from taking such drugs as phenothiazines, thiouracil and chloramphenicol. Other causes: radiation therapy, leukaemia, aplastic anaemia.

Symptoms: sore mouth, throat and lungs with bacterial infection.

Treatment: Should be supportive to specific medical treatment. Stop drugs that may be causative. Select from:–

Angelica, Burdock leaves, Calamus, Chamomile, Chickweed, Comfrey, Dandelion, Ginseng, Ground Ivy, Gotu Kola, Iceland Moss, Irish Moss, Liquorice root. Lime flowers, Linseed, Marshmallow leaves, Mullein leaves, Plantain, Red Clover flowers, Thuja, Violet leaves.

Tea. Combine equal parts: Red Clover, Gotu Kola, Mullein. 1 heaped teaspoon to each cup boiling water; infuse 10-15 minutes; dose, half-1 cup freely, as tolerated.

Tablets/capsules: Goldenseal, Echinacea, Iceland Moss, Ginseng. Dosage as on bottle.

Powders: Formula. Red Clover 2; Ginseng 1; Echinacea 1. Dose: 750mg (or three 00 capsules or half a teaspoon) thrice daily.

Tinctures. Combine Echinacea 2; Goldenseal 1; Fringe Tree 1. Dose: 1-2 teaspoons in water thrice daily. Topical: Epsom’s salts baths.

Diet: High protein, high fibre, low fat, low salt, regular raw food days. Vitamins C, B-complex (especially B12), folic acid, bioflavonoids. Minerals – copper, iron, zinc. 

Health Source: Bartrams Encyclopedia of Herbal Medicine
Author: Health Encyclopedia
A condition in which the white cells or LEUCOCYTES in the blood of the polynuclear or granular variety become greatly lessened in numbers or disappear altogether. It is usually caused by taking such drugs as amidopyrine, thiourea, sulphonamides, chloramphenicol and the immunosuppressant drugs.
Health Source: Medical Dictionary
Author: Health Dictionary
n. a disorder in which there is a severe acute deficiency of certain blood cells (*neutrophils) as a result of damage to the bone marrow by toxic drugs or chemicals. It is characterized by fever, with ulceration of the mouth and throat, and may lead rapidly to prostration and death. Treatment is by the administration of antibiotics in large quantities. When feasible, transfusion of white blood cells may be life-saving.
Health Source: Oxford | Concise Colour Medical Dictionary
Author: Jonathan Law, Elizabeth Martin

Clozapine

An antipsychotic drug used to treat schizophrenic patients (see SCHIZOPHRENIA) who have not responded to other treatments or who have suffered serious side-effects from them. Improvement is gradual and it may be several weeks before severe symptoms are relieved. The drug can cause AGRANULOCYTOSIS and so it is given under close hospital supervision.... clozapine

Colchicum Luteum

Baker.

Family: Liliaceae.

Habitat: The temperate Himalayas from Kashmir to Chamba. Major supplies of the drug are received from Kashmir.

English: Hermodactyls, Colchicum, Meadow Saffron, Golden Collyrium (Indian substitute). (C. luteum is a good substitute for C. autumnale L. which is official in the B.P.)

Ayurvedic: Hiranyatuttha.

Unani: Suranjaan Talkh.

Action: Non-steroidal antiinflammatory, anti-gout (relieves inflammation and pain of acute gout but does not increase expulsion of uric acid, is used with an alkaline diuretic), emetic, cathartic. Anti-chemotactic, antiphlogistic, inhibitor of mitosis. Highly toxic. Used for external application to lessen inflammation and pain.

Key application: In acute gout attack. (German Commission E.)

The fresh corms and aerial parts of a sample from Jammu yielded 0.94% and 070% of total alkaloids, the major being colchicine 0.40% and 0.20% respectively. Colchicine analogs— decteyl thiocolchicine (DTC), decetyl- methylcolchicine (DMC) and tri- methylcolchicinic acid (TMCA) were effective in the treatment of gout; DTC may elicit agranulocytosis.

Colchicine binds to tubulin, the protein subunit of microtubules. Its most important biological effect is the inhibition of processes that depend upon microtubule function by blocking polymerization. In preventing micro- tubule formation, colchicine has been shown to inhibit catecholamine secretion from adrenal medulla, iodine secretion from thyroid gland and pro- lactin secretion from pituitary tumour cells. It inhibits stimulated insulin secretion from isolated perfused pancreas and islets in vitro.

The use of Colchicum for long periods is not recommended owing to its toxicity in larger doses (even 7 mg of colchicine has caused death) and its depressant action upon central nervous system.

Prolonged use of Colchicum autum- nale may cause agranulocytosis, aplas- tic anaemia and peripheral nerve inflammation. (Sharon M. Herr.)... colchicum luteum

Phenindione

A synthetic anticoagulant (see ANTICOAGULANTS). Given by mouth, it is used to prevent the formation of clots in the blood in rheumatic heart disease and atrial ?brillation (see HEART, DISEASES OF); as prophylaxis after insertion of a prosthetic heart valve; and as prophylaxis and treatment of venous thrombosis and pulmonary embolism. It is slower in action than WARFARIN, not achieving its full anticoagulant e?ect until up to 48 hours after the initial dose. The drug should be avoided in patients with renal or hepatic impairment, and whenever severe hypersensitivity reactions have previously occurred. Adverse effects include rashes, fever, LEUCOPENIA, AGRANULOCYTOSIS, diarrhoea and pink urine; breast feeding should be avoided.... phenindione

Hypoglycaemic Agents

These oral agents reduce the excessive amounts of GLUCOSE in the blood (HYPERGLYCAEMIA) in people with type 2 (INSULIN-resistant) diabetes (see DIABETES MELLITUS). Although the various drugs act di?erently, most depend on a supply of endogenous (secreted by the PANCREAS) insulin. Thus they are of no value in treating patients with type 1 diabetes (insulin-dependent diabetes mellitus (IDDM), in which the pancreas produces little or no insulin and the patient’s condition is stabilised using insulin injections). The traditional oral hypoglycaemic drugs have been the sulphonylureas and biguanides; new agents are now available – for example, thiazolidine-diones (insulin-enhancing agents) and alpha-glucosidase inhibitors, which delay the digestion of CARBOHYDRATE and the absorption of glucose. Hypoglycaemic agents should not be prescribed until diabetic patients have been shown not to respond adequately to at least three months’ restriction of energy and carbohydrate intake.

Sulphonylureas The main group of hypoglycaemic agents, these act on the beta cells to stimulate insulin release; consequently they are e?ective only when there is some residual pancreatic beta-cell activity (see INSULIN). They also act on peripheral tissues to increase sensitivity, although this is less important. All sulphonylureas may lead to HYPOGLYCAEMIA four hours or more after food, but this is relatively uncommon, and usually an indication of overdose.

There are several di?erent sulphonylureas; apart from some di?erences in their duration or action (and hence in their suitability for individual patients) there is little di?erence in their e?ectiveness. Only chlorpropamide has appreciably more side-effects – mainly because of its prolonged duration of action and consequent risk of hypoglycaemia. There is also the common and unpleasant chlorpropamide/ alcohol-?ush phenomenon when the patient takes alcohol. Selection of an individual sulphonylurea depends on the patient’s age and renal function, and often just on personal preference. Elderly patients are particularly prone to the risks of hypoglycaemia when long-acting drugs are used. In these patients chlorpropamide, and preferably glibenclamide, should be avoided and replaced by others such as gliclazide or tolbutamide.

These drugs may cause weight gain and are indicated only if poor control persists despite adequate attempts at dieting. They should not be used during breast feeding, and caution is necessary in the elderly and in those with renal or hepatic insu?ciency. They should also be avoided in porphyria (see PORPHYRIAS). During surgery and intercurrent illness (such as myocardial infarction, COMA, infection and trauma), insulin therapy should be temporarily substituted. Insulin is generally used during pregnancy and should be used in the presence of ketoacidosis.

Side-effects Chie?y gastrointestinal disturbances and headache; these are generally mild and infrequent. After drinking alcohol, chlorpropamide may cause facial ?ushing. It also may enhance the action of antidiuretic hormone (see VASOPRESSIN), very rarely causing HYPONATRAEMIA.

Sensitivity reactions are very rare, usually occurring in the ?rst six to eight weeks of therapy. They include transient rashes which rarely progress to erythema multiforme (see under ERYTHEMA) and exfoliate DERMATITIS, fever and jaundice; chlorpropamide may also occasionally result in photosensitivity. Rare blood disorders include THROMBOCYTOPENIA, AGRANULOCYTOSIS and aplastic ANAEMIA.

Biguanides Metformin, the only available member of this group, acts by reducing GLUCONEOGENESIS and by increasing peripheral utilisation of glucose. It can act only if there is some residual insulin activity, hence it is only of value in the treatment of non-insulin dependent (type 2) diabetics. It may be used alone or with a sulphonylurea, and is indicated when strict dieting and sulphonylurea treatment have failed to control the diabetes. It is particularly valuable in overweight patients, in whom it may be used ?rst. Metformin has several advantages: hypoglycaemia is not usually a problem; weight gain is uncommon; and plasma insulin levels are lowered. Gastrointestinal side-effects are initially common and persistent in some patients, especially when high doses are being taken. Lactic acidosis is a rarely seen hazard occurring in patients with renal impairment, in whom metformin should not be used.

Other antidiabetics Acarbose is an inhibitor of intestinal alpha glucosidases (enzymes that process GLUCOSIDES), delaying the digestion of starch and sucrose, and hence the increase in blood glucose concentrations after a meal containing carbohydrate. It has been introduced for the treatment of type 2 patients inadequately controlled by diet or diet with oral hypoglycaemics.

Guar gum, if taken in adequate doses, acts by delaying carbohydrate absorption, and therefore reducing the postprandial blood glucose levels. It is also used to relieve symptoms of the DUMPING SYNDROME.... hypoglycaemic agents

Captopril

n. a drug used in the treatment of heart failure, hypertension, and diabetic nephropathy; it acts by inhibiting the action of angiotensin (see ACE inhibitor). Side-effects include rash, *neutropenia or *agranulocytosis, hypotension, and loss of taste.... captopril

Neutropenia

n. an abnormal decrease in the number of *neutrophils in peripheral blood. Neutropenia may occur in a wide variety of diseases, including certain hereditary defects, aplastic *anaemias, tumours of the bone marrow, *agranulocytosis, and acute leukaemias. In cancer patients it is often due to the deleterious effects of *cytotoxic drugs on bone marrow cells. Neutropenia results in an increased susceptibility to infections; if patients become unwell, due to infection, this can lead to neutropenic sepsis, which can be life-threatening. —neutropenic adj.... neutropenia

Schizophrenia

An overall title for a group of psychiatric disorders typ?ed by disturbances in thinking, behaviour and emotional response. Despite its inaccurate colloquial description as ‘split personality’, schizophrenia should not be confused with MULTIPLE PERSONALITY DISORDER. The illness is disabling, running a protracted course that usually results in ill-health and, often, personality change. Schizophrenia is really a collection of symptoms and signs, but there is no speci?c diagnostic test for it. Similarity in the early stages to other mental disorders, such as MANIC DEPRESSION, means that the diagnosis may not be con?rmed until its response to treatment and its outcome can be assessed and other diseases excluded.

Causes There is an inherited element: parents, children or siblings of schizophrenic sufferers have a one in ten chance of developing the disorder; a twin has a 50 per cent chance if the other twin has schizophrenia. Some BRAIN disorders such as temporal lobe EPILEPSY, tumours and ENCEPHALITIS seem to be linked with schizophrenia. Certain drugs – for example, AMPHETAMINES – can precipitate schizophrenia and DOPAMINE-blocking drugs often relieve schizophrenic symptoms. Stress may worsen schizophrenia and recreational drugs may trigger an attack.

Symptoms These usually develop gradually until the individual’s behaviour becomes so distrubing or debilitating that work, relationships and basic activities such as eating and sleeping are interrupted. The patient may have disturbed perception with auditory HALLUCINATIONS, illogical thought-processes and DELUSIONS; low-key emotions (‘?at affect’); a sense of being invaded or controlled by outside forces; a lack of INSIGHT and inability to acknowledge reality; lethargy and/or agitation; a disrespect for personal appearance and hygiene; and a tendency to act strangely. Violence is rare although some sufferers commit violent acts which they believe their ‘inner voices’ have commanded.

Relatives and friends may try to cope with the affected person at home, but as severe episodes may last several months and require regular administration of powerful drugs – patients are not always good at taking their medication

– hospital admission may be necessary.

Treatment So far there is no cure for schizophrenia. Since the 1950s, however, a group of drugs called antipsychotics – also described as NEUROLEPTICS or major tranquillisers – have relieved ?orid symptoms such as thought disorder, hallucinations and delusions as well as preventing relapses, thus allowing many people to leave psychiatric hospitals and live more independently outside. Only some of these drugs have a tranquillising e?ect, but their sedative properties can calm patients with an acute attack. CHLORPROMAZINE is one such drug and is commonly used when treatment starts or to deal with an emergency. Halperidol, tri?uoperazine and pimozide are other drugs in the group; these have less sedative effects so are useful in treating those whose prominent symptoms are apathy and lethargy.

The antipsychotics’ mode of action is by blocking the activity of DOPAMINE, the chemical messenger in the brain that is faulty in schizophrenia. The drugs quicken the onset and prolong the remission of the disorder, and it is very important that patients take them inde?nitely. This is easier to ensure when a patient is in hospital or in a stable domestic environment.

CLOZAPINE – a newer, atypical antipsychotic drug – is used for treating schizophrenic patients unresponsive to, or intolerant of, conventional antipsychotics. It may cause AGRANULOCYTOSIS and use is con?ned to patients registered with the Clorazil (the drug’s registered name) Patient Monitoring Service. Amisulpride, olanzapine, quetiapine, risperidone, sertindole and zotepine are other antipsychotic drugs described as ‘atypical’ by the British National Formulary; they may be better tolerated than other antipsychotics, and their varying properties mean that they can be targeted at patients with a particular grouping of symptoms. They should, however, be used with caution.

The welcome long-term shift of mentally ill patients from large hospitals to community care (often in small units) has, because of a lack of resources, led to some schizophrenic patients not being properly supervised with the result that they fail to take their medication regularly. This leads to a recurrence of symptoms and there have been occasional episodes of such patients in community care becoming a danger to themselves and to the public.

The antipsychotic drugs are powerful agents and have a range of potentially troubling side-effects. These include blurred vision, constipation, dizziness, dry mouth, limb restlessness, shaking, sti?ness, weight gain, and in the long term, TARDIVE DYSKINESIA (abnormal movements and walking) which affects about 20 per cent of those under treatment. Some drugs can be given by long-term depot injection: these include compounds of ?upenthixol, zuclopenthixol and haloperidol.

Prognosis About 25 per cent of sufferers recover fully from their ?rst attack. Another 25 per cent are disabled by chronic schizophrenia, never recover and are unable to live independently. The remainder are between these extremes. There is a high risk of suicide.... schizophrenia




Recent Searches